The article argues that moving discovery compounds into first-in-human (Phase 1) and first-in-patient (Phase 2) studies is a major challenge for the industry. A rational, phase-appropriate formulation strategy is needed to avoid costly failures and to speed development cost-effectively, especially for poorly soluble or poorly bioavailable compounds.
At this stage, API supply is limited, and it is hard to pick a bioavailable formulation for animal PK, GLP toxicity, and human studies. The recommended starting point is pre-formulation work: checking solubility and stability in common solvents and biorelevant media, measuring permeability, and then screening delivery systems. Simple formulations such as solutions, suspensions, and drug-in-capsule are preferred for speed, but adequate systemic exposure comes first.
Formulation choice depends on several factors. Route, dose, and solubility decide between a solution and a suspension. Dose flexibility matters because the maximum tolerated human dose is not yet known. Blinding is another factor: taste or color differences between active and placebo have to be managed. So is where dosing happens, because in-hospital and outpatient dosing have different shelf-life and storage needs.
The article describes four dosage-form options:
The article also names Ascendia Pharmaceutical Solutions' AmorSol®, NanoSol® and EmulSol® platforms.
It is a formulation approach matched to the needs of the current clinical stage rather than to the final commercial product. For Phase 1 and 2, the formulation has to deliver adequate systemic exposure, allow flexible dosing, fit the study design (such as blinding) and keep to tight timelines, all while API supply is limited.
A poorly chosen formulation can give inadequate drug exposure. A compound can then fail in Phase 1 or later because the formulation didn’t work, not because the molecule was flawed. A rational strategy reduces costly failures and speeds the path to the clinic. This matters most for poorly soluble or poorly bioavailable compounds.
Solubility and stability testing in common solvents and biorelevant media, permeability assessment, and screening of delivery systems to improve solubility and bioavailability. These results guide the formulation used for animal PK, GLP toxicology, and human dosing.
There are four main options:
Simple forms are preferred for speed, as long as they give enough exposure.
Drug-in-bottle suits in-hospital dosing where dose flexibility is needed, and stability data are limited. Drug-in-capsule suits outpatient and blinded studies when the API wets and dissolves well in GI fluids without excipients.
The route, the dose requirement, and the compound’s solubility decide it. If both are used across studies, a biopharmaceutical bridging assessment is needed, and each form needs its own stability data and handling instructions.
Taste and appearance differences between active and placebo have to be masked. For liquids, this can mean bittering agents. Other options are colored packaging, syringes, or dosing cups. Pediatric studies may also need taste masking.
Amorphous solid dispersions, nanosuspensions, and lipid-based systems such as SEDDS and nanoemulsions. Ascendia Pharmaceuticals’ platforms for these are AmorSol®, NanoSol®, and EmulSol®.
Outpatient studies need longer shelf life and simple storage. Ready-to-use liquids stored at room temperature or refrigerated, or capsules, are usually preferred over pharmacy-reconstituted products.